Jun 2026 (Q2 FY26) — Aug 5, 2026
MannKind Q2 FY26 — Strong Afrezza Pediatric Launch and Furoscix ReadyFlow Approval
Read the full callMannKind (MNKD) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
MannKind earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 109 | +42.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -0.3 | −7.2 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -19.0 | −2949.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$3.09 +1.64% · +$0.05
Performance −43.5% 1Y
1Y: $5.47 on 17 Oct 2025 → $3.09. High $6.21 (3 Feb 2026), low $2.28 (25 Mar 2026).
- Previous close
- $3.04
- 52-week range
- $2.28 – $6.21
- One year
- −43.72%
Overview
- Symbol
- MNKD
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
MannKind earnings calls (MNKD)
Financials
What the filings say
Net profit, year on year: −2949% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 70 | 77 | 78 | 77 | 82 | 112 | 90 | 109 |
| Expenses | 57 | 50 | 56 | 71 | 63 | 120 | 92 | 110 |
| Operating profit | 13 | 26 | 22 | 5 | 19 | -8 | -2 | -0 |
| Operating margin | 18.2% | 34.5% | 28.4% | 6.9% | 23.0% | −6.9% | −1.9% | −0.3% |
| Other income | 0 | -18 | -9 | -4 | -11 | -13 | -15 | -19 |
| Interest | 2 | 2 | 5 | 0 | 1 | 8 | 7 | 12 |
| Profit before tax | 13 | 8 | 14 | 1 | 8 | -21 | -16 | -19 |
| Tax rate | 10.3% | 12.1% | 3.4% | 28.9% | −2.6% | 23.8% | −1.6% | 0.6% |
| Net profit | 12 | 7 | 13 | 1 | 8 | -16 | -17 | -19 |
| EPS ($ per share) | 0.04 | — | 0.04 | 0 | 0.03 | — | -0.05 | -0.06 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| Reserves | -2,940 | -2,992 | -3,049 | -3,130 | -3,217 | -3,229 | -3,202 | -3,196 |
| Total liabilities | 283 | 284 | 289 | 531 | 546 | 721 | 473 | 843 |
| Fixed assets | 26 | 27 | 26 | 37 | 45 | 84 | 85 | 82 |
| Investments | — | 20 | 0 | 80 | 101 | 57 | 151 | 96 |
| Total assets | 108 | 94 | 109 | 321 | 295 | 475 | 394 | 792 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -38 | -88 | -28 | -62 | -81 | 34 | 43 | 18 |
| Cash from investing | -0 | -23 | 15 | -152 | 5 | -2 | -97 | -305 |
| Cash from financing | 61 | 70 | 50 | 270 | 21 | 137 | -137 | 315 |
| Net cash flow | 23 | -41 | 37 | 57 | -54 | 169 | -191 | 29 |
| Capital expenditure | -0 | -3 | -1 | -11 | -8 | -42 | -10 | -5 |
| Free cash flow | -38 | -91 | -29 | -73 | -88 | -8 | 33 | 14 |
Insider filings
64 filings between Oct 31, 2025 and Sep 25, 2026.
Open market
decisions to buy or sellPurchases
$259.0K
1 purchase by 1 insider
Sales
$3.26M
14 sales by 5 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 9
- Award — granted as compensation
- 11
- Option exercise — converted options into shares
- 28
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Castagna Michael | $259.0K | $1.25M | Mar 10, 2026 |
| Thomson David | — | $930.8K | Jul 17, 2026 |
| Binder Steven B. | — | $683.7K | Sep 25, 2026 |
| Tross Stuart A | — | $297.5K | Jan 8, 2026 |
| Singh Sanjay R | — | $94.4K | Nov 14, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 25, 2026 | Binder Steven B. Director | Sale 10b5-1 plan | 39,051 | $128.5K |
| Sep 10, 2026 | Binder Steven B. Director | Sale 10b5-1 plan | 33,558 | $127.9K |
| Aug 7, 2026 | Binder Steven B. Director | Sale 10b5-1 plan | 39,051 | $158.5K |
| Jul 17, 2026 | Binder Steven B. Director | Sale 10b5-1 plan | 52,485 | $213.1K |
| Jul 17, 2026 | Thomson David EVP Genl Counsel & Secretary | Sale 10b5-1 plan | 24,109 | $97.6K |
| Jul 15, 2026 | Singh Sanjay R EVP Technical Operations | Tax withheld | 5,372 | $22.0K |
| Jul 15, 2026 | Binder Steven B. Director | Option exercise 10b5-1 plan | 93,790 | $0 |
| Jul 15, 2026 | Tross Stuart A Chief People & Workpl Officer | Tax withheld | 8,253 | $33.8K |
| Jul 15, 2026 | Castagna Michael Chief Executive Officer | Tax withheld | 58,904 | $240.9K |
| Jul 15, 2026 | Singh Sanjay R EVP Technical Operations | Tax withheld | 9,297 | $38.0K |
| Jul 15, 2026 | Tross Stuart A Chief People & Workpl Officer | Tax withheld | 33,652 | $137.6K |
| Jul 15, 2026 | Thomson David EVP Genl Counsel & Secretary | Tax withheld 10b5-1 plan | 12,662 | $51.8K |
| Jul 15, 2026 | Thomson David EVP Genl Counsel & Secretary | Tax withheld 10b5-1 plan | 17,754 | $72.6K |
| Jul 15, 2026 | Binder Steven B. Director | Tax withheld 10b5-1 plan | 15,688 | $64.2K |
| Jul 15, 2026 | Castagna Michael Chief Executive Officer | Tax withheld | 47,481 | $194.2K |
| Jul 15, 2026 | Castagna Michael Chief Executive Officer | Tax withheld | 192,819 | $788.6K |
| Jul 15, 2026 | Castagna Michael Chief Executive Officer | Option exercise | 350,260 | $0 |
| Jul 15, 2026 | Singh Sanjay R EVP Technical Operations | Tax withheld | 10,079 | $41.2K |
| Jul 15, 2026 | Singh Sanjay R EVP Technical Operations | Option exercise | 70,550 | $0 |
| Jul 15, 2026 | Castagna Michael Chief Executive Officer | Tax withheld | 63,996 | $261.7K |
| Jul 15, 2026 | Thomson David EVP Genl Counsel & Secretary | Option exercise 10b5-1 plan | 93,790 | $0 |
| Jul 15, 2026 | Tross Stuart A Chief People & Workpl Officer | Option exercise | 93,790 | $0 |
| Jul 15, 2026 | Thomson David EVP Genl Counsel & Secretary | Tax withheld 10b5-1 plan | 51,632 | $211.2K |
| Jul 15, 2026 | Singh Sanjay R EVP Technical Operations | Tax withheld | 22,047 | $90.2K |
| Jul 15, 2026 | Tross Stuart A Chief People & Workpl Officer | Tax withheld | 11,572 | $47.3K |
| Jul 15, 2026 | Tross Stuart A Chief People & Workpl Officer | Tax withheld | 12,331 | $50.4K |
| Jul 15, 2026 | Marasco Dominic Pres, Endocrine Business Unit | Tax withheld | 3,623 | $14.8K |
| Jul 15, 2026 | Prentiss Christopher B Chief Financial Officer | Tax withheld | 11,572 | $47.3K |
| Jul 15, 2026 | Prentiss Christopher B Chief Financial Officer | Tax withheld | 10,675 | $43.7K |
| Jul 15, 2026 | Thomson David EVP Genl Counsel & Secretary | Tax withheld 10b5-1 plan | 16,378 | $67.0K |
| Jul 15, 2026 | Binder Steven B. Director | Tax withheld 10b5-1 plan | 4,073 | $16.7K |
| Jul 15, 2026 | Binder Steven B. Director | Tax withheld 10b5-1 plan | 4,634 | $19.0K |
| May 20, 2026 | Marasco Dominic Pres, Endocrine Business Unit | Award | 8,474 | $25.0K |
| May 20, 2026 | Consiglio Ronald J Director | Award | 10,000 | $29.5K |
| May 20, 2026 | Tross Stuart A Chief People & Workpl Officer | Award | 33,898 | $100.0K |
| May 12, 2026 | Binder Steven B. Director | Sale 10b5-1 plan | 16,940 | $55.7K |
| May 12, 2026 | Thomson David EVP Genl Counsel & Secretary | Sale 10b5-1 plan | 3,033 | $10.0K |
| May 11, 2026 | Thomson David EVP Genl Counsel & Secretary | Tax withheld 10b5-1 plan | 12,387 | $43.6K |
| May 11, 2026 | Castagna Michael Chief Executive Officer | Tax withheld | 34,957 | $123.0K |
| May 11, 2026 | Tross Stuart A Chief People & Workpl Officer | Tax withheld | 8,073 | $28.4K |
| May 11, 2026 | Binder Steven B. Director | Tax withheld 10b5-1 plan | 5,560 | $19.6K |
| Apr 22, 2026 | Prentiss Christopher B Chief Financial Officer | Tax withheld | 12,267 | $33.6K |
| Mar 10, 2026 | Castagna Michael Chief Executive Officer | Purchase | 100,000 | $259.0K |
| Mar 1, 2026 | Shannon James Samuel Director | Award | 12,000 | $39.2K |
| Mar 1, 2026 | HOOPER ANTHONY C Director | Award | 35,000 | $114.5K |
| Mar 1, 2026 | Prentiss Christopher B Chief Financial Officer | Award | 5,000 | $16.4K |
| Mar 1, 2026 | Castagna Michael Chief Executive Officer | Award | 15,290 | $50.0K |
| Mar 1, 2026 | Tross Stuart A Chief People & Workpl Officer | Award | 15,290 | $50.0K |
| Jan 8, 2026 | Tross Stuart A Chief People & Workpl Officer | Sale 10b5-1 plan | 47,006 | $297.5K |
| Dec 24, 2025 | Castagna Michael Chief Executive Officer | Gift | 44,171 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for MANNKIND CORP
Free account. Everything above stays public.
Write why you follow MANNKIND CORP and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading